IMBdx

IMBdx develops blood-based cancer tests that detect tumour DNA circulating in a patient's bloodstream, a technique called liquid biopsy, allowing cancer to be diagnosed, monitored after surgery, or screened for early without removing tissue from the body.

Its tests serve cancer patients and clinicians across three areas: profiling advanced cancers to guide treatment, detecting early signs of recurrence after surgery, and screening for cancer before symptoms appear. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company combines liquid biopsy with next-generation sequencing, a method that reads millions of genetic fragments simultaneously, to cover the full cancer-care continuum within a single product portfolio.